ReviewHepatic oncology2015
Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.
Review in Hepatic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Hepatic Recurrence Rate Based on Extent of Adjuvant Floxuridine Exposure After Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- An RNA damage response network mediates the lethality of 5-FU in colorectal cancer.Cell reports. Medicine · 2024Article
- Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.Annals of surgical oncology · 2023Article
- A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy.Clinical colorectal cancer · 2023Article
- An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types.bioRxiv : the preprint server for biology · 2023Article
- Stent Graft Placement for the Treatment of Hepatic Artery Injury in Patients with Cancer: Primary Patency and Clinical Outcomes.Journal of vascular and interventional radiology : JVIR · 2023Article
- Nuclear imaging in the identification of aberrant vascular anatomy prior to hepatic arterial infusion.Radiology case reports · 2022Article
- Intra-Arterial Infusion Chemotherapy in Advanced Pancreatic Cancer: A Comprehensive Review.Cancers · 2022Review
- Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.Frontiers in endocrinology · 2022Article
- Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model.Drug delivery and translational research · 2021Article
- Review
- Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments.Cancers · 2020Article
- Do hepatic artery infusion pumps cause recurrent pleural effusions?Journal of surgical case reports · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal liver metastases (CRLM) receive their blood supply predominantly through the hepatic artery. Intra-arterial drug delivery can optimize the dose and time exposure of chemotherapy to tumor cells while limiting systemic toxicity. Chemotherapy is most commonly administered through a catheter surgically placed in the gastroduodenal artery and connected to a subcutaneous pump. Due to its pharmacokinetics features, floxuridine is the most commonly used drug in the USA with hepatic arterial infusional (HAI) chemotherapy. To date, many clinical trials have shown the positive impact of HAI in the management of CRLM. Hence, in unresectable patients, HAI is associated with high response rates and commonly enables subsequent resection in both chemonaive and previously treated patients. Outcomes in patients converted to complete resection are similar to patients who present with initially resectable disease. In the adjuvant setting, HAI with floxuridine improves survival as well as hepatic and overall disease-free survival after complete resection of CRLM, as compared with 5-FU alone, in three of four randomized studies. To date, no trials have compared HAI combined with modern chemotherapy alone to modern chemotherapy alone in the adjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.